Skip to main content
. 2019 Dec 30;117(1):541–551. doi: 10.1073/pnas.1902145116

Fig. 3.

Fig. 3.

Myeloid cell skewing by Ang2/VEGFA blockade in combination with agonist CD40 antibodies. (A) Flow cytometry analysis of tumor-infiltrating F4/80+ TAMs (CD11b+Ly6G−Ly6C−F4/80+) in mice bearing MC38 tumors (Left). TAMs were further assessed for expression of the M2 marker CD206/MRC1 (Middle) and the ratio between M1 (CD11c+) and M2 (CD206+) TAMs (Right). Each data point represents one mouse. (B) Flow cytometry analyses of tumor infiltrating TAMs (Left) as well as assessment of M2 marker (Middle) and the ratio between M1 and M2 TAMs (Right) was performed as per A in B16-OVA tumor-bearing mice. Each data point represents one mouse. (C) Flow cytometry analyses of tumor-infiltrating TAMs in mice bearing MMTV-PyMT tumors. Each data point represents one mouse. (D) Flow cytometry analysis of APCs in B16-OVA tumor-bearing mice. Data represent mean fluorescence intensity (MFI) of CD86 (Left) or MHC-II (Middle) on CD11chi (F4/80−) APCs and MFI of SIINFEKL peptide in complex with H-2Kb major histocompatibility on CD11chiMHC-IIhi APCs (Right) after gating on CD11b+Ly6G−Ly6C−F4/80− cells. Each data point represents one mouse. Data indicate mean values ± SEM. Statistical analyses by 1-way ANOVA with Tukey’s correction for multiple comparisons (black) or pairwise Student’s t test (red), unless otherwise indicated in Dataset S2. The number of mice employed in each experiment is reported in Dataset S2.